Reunion Neuroscience Inc. (REUN)

NASDAQ: REUN · IEX Real-Time Price · USD
1.75
-0.20 (-10.26%)
At close: Sep 23, 2022 4:00 PM
1.74
-0.01 (-0.57%)
After-hours: Sep 23, 2022 6:41 PM EDT
-10.26%
Market Cap 20.09M
Revenue (ttm) 5.82M
Net Income (ttm) n/a
Shares Out 11.48M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date Aug 17, 2022
Volume 15,648
Open 1.95
Previous Close 1.95
Day's Range 1.75 - 1.95
52-Week Range 0.71 - 6.41
Beta n/a
Analysts Buy
Price Target 145.52 (+8,215.4%)
Earnings Date n/a

About REUN

Field Trip Health Ltd. engages in the development and delivery of psychedelic- assisted therapies in North America. The company operates Field Trip Health Centres that provide psychedelic therapies; offers Field Trip Digital apps; operates Field Trip Discovery, a drug development division that develops the next generation of psychedelic molecules; and provides ketamine-assisted therapy for the treatment of depression, anxiety, addiction, and other conditions. Field Trip Health Ltd. was founded in 2008 and is headquartered in Toronto, Canada. [Read more...]

Industry Biotechnology
Founded 2008
Employees 194
Stock Exchange NASDAQ
Ticker Symbol REUN
Full Company Profile

Financial Performance

In 2021, REUN's revenue was $4.86 million, an increase of 405.79% compared to the previous year's $960,895. Losses were -$54.69 million, 136.6% more than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for REUN stock is "Buy." The 12-month stock price forecast is 145.52, which is an increase of 8,215.43% from the latest price.

Price Target
$145.52
(8,215.43% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Reunion Neuroscience Inc. to Participate in Upcoming Investor Conferences

TORONTO, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) ("Reunion"), or (“the Company”), a global leader in the discovery and development of innovative psychedeli...

2 weeks ago - GlobeNewsWire

Reunion Neuroscience Inc. Announces 2022 Annual General Meeting of Shareholders

TORONTO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) ("Reunion"), or (“the Company”), a global leader in the discovery and development of innovative of psychede...

3 weeks ago - GlobeNewsWire

Reunion Neuroscience Inc. to Commence Trading on the Toronto Stock Exchange on August 17, 2022

TORONTO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (formerly, Field Trip Health Ltd., the "Company" or “Reunion”), a global leader in the discovery and development of innovative of psy...

1 month ago - GlobeNewsWire

Reunion Neuroscience Inc. (Formerly Field Trip Health Ltd.) Reports Fiscal First Quarter 2023 Financial Results, Comp...

TORONTO, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (formerly “Field Trip Health Ltd.”, or the “Company”) (TSX: FTRP, Nasdaq: FTRP), a leader in novel psychedelic drug development, repo...

1 month ago - GlobeNewsWire

Field Trip Health & Wellness Ltd. Provides Update on TSX Venture Exchange Listing

TORONTO, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Field Trip Health & Wellness Ltd. (the "Company") is pleased to announce that it has filed a listing application in connection with the previously announced in...

1 month ago - GlobeNewsWire

Field Trip Announces Closing of Plan of Arrangement and $19.9 Million Private Placement Financing

- Field Trip Health Ltd. has been renamed "Reunion Neuroscience Inc." and remains listed on the NASDAQ Stock Market and Toronto Stock Exchange under the ticker symbol "FTRP" with such ticker symbol chan...

1 month ago - GlobeNewsWire

Field Trip Health Ltd. (FTRP) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Field Trip Health Ltd. (FTRP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

1 month ago - Zacks Investment Research

Field Trip Health Ltd. Receives Conditional Approval for Listing of Common Shares of Field Trip Health & Wellness Ltd.

– Field Trip Health & Wellness Ltd. to list on the TSX Venture Exchange, with first day of trading expected to occur on or about August 17, 2022. – Field Trip Discovery to be renamed Reunion Neuroscienc...

1 month ago - GlobeNewsWire

Field Trip Announces First Dosings in Phase I Clinical Study of FT-104

- First Dosings completed in Australia - Provides Update on Pending Spin-Out and Renaming to Reunion Neurosciences - Announces 5:1 Share Consolidation Ratio

2 months ago - GlobeNewsWire

Field Trip Health Ltd. Reports Fiscal Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updat...

TORONTO, June 29, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; NASDAQ: FTRP) ("Field Trip"), a leader in the development and delivery of psychedelic therapies, reported fiscal fo...

2 months ago - GlobeNewsWire

Field Trip Health Ltd. Receives Final Court Approval for Reorganization of the Discovery and Wellness Businesses Into...

- Closing of arrangement subject to regulatory approvals, including conditional listing approval by the TSX Venture Exchange. - Closing of the arrangement expected to occur in August. - Also announces c...

2 months ago - GlobeNewsWire

Field Trip Health Ltd. Announces Voting Results From Special Shareholder Meeting

Approves spin-out of clinics business to Field Trip Health & Wellness Ltd., pending final court approval and additional customary closing conditions Approves spin-out of clinics business to Field Trip H...

2 months ago - GlobeNewsWire

Field Trip Health Ltd. to Present at the H.C.

TORONTO, June 23, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced t...

3 months ago - GlobeNewsWire

Field Trip Health Ltd. Schedules Fiscal Fourth Quarter and Full Year 2022 Results Conference Call for Thursday, June ...

- Discloses Receipt Of Nasdaq Non-Compliance With Minimum Price Notice - Discloses Receipt Of Nasdaq Non-Compliance With Minimum Price Notice

3 months ago - GlobeNewsWire

Field Trip Health Ltd. Announces Increased Participation in Arrangement Financing and Postponement of Shareholder Mee...

TORONTO, June 14, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) (the "Company" or "Field Trip"), a global leader in the development and delivery of psychedelic thera...

3 months ago - GlobeNewsWire

Field Trip and Nue Life Are Collaborating To Bring Psychedelic Therapy Into the Home

TORONTO, May 12, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) ("Field Trip"), a leader in the development and delivery of psychedelic-assisted psychotherapy with 12 location...

4 months ago - GlobeNewsWire

Field Trip Health Ltd. to Participate in Upcoming Investor Conferences in May 2022

TORONTO, April 29, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced ...

4 months ago - GlobeNewsWire

Field Trip Health Ltd. Announces Intention to Separate the Field Trip Discovery and Field Trip Health Divisions Into ...

TORONTO, April 28, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) (the "Company"), a global leader in the development and delivery of psychedelic therapies, announced...

4 months ago - GlobeNewsWire

Field Trip Health Ltd. to Participate in Upcoming Investor Conferences

TORONTO, April 18, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced ...

5 months ago - GlobeNewsWire

Field Trip Health Ltd. Granted US Patent Covering Novel Psychedelic Molecule FT-104

The Allowed Claims include Composition of FT-104 and Provides Protection until 2040 The Allowed Claims include Composition of FT-104 and Provides Protection until 2040

5 months ago - GlobeNewsWire

3 Psychedelic Stocks to Buy for Oregon's Magic Mushroom Bill

Psychedelic medical treatments and therapies are gaining in popularity, and these psychedelic stocks could benefit as the market emerges. The post 3 Psychedelic Stocks to Buy for Oregon's Magic Mushroom...

Other symbols: CYBNMNMD
5 months ago - InvestorPlace

Field Trip Health Ltd. to Participate in Maxim Group 2nd Annual Virtual Growth Conference

TORONTO, March 23, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced ...

6 months ago - GlobeNewsWire

Field Trip Health Ltd. to Participate in 34th Annual Roth Conference in March 2022

TORONTO, March 09, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced ...

6 months ago - GlobeNewsWire

Field Trip Health and Cerebral Partner to Provide End-to-End Mental Health Care

TORONTO, March 3, 2022 /PRNewswire/ -- Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic-assisted psychotherapy, today annou...

6 months ago - PRNewsWire

Field Trip Health Posts 330% YoY Increase In Q3 Revenue

Psychedelics-based company Field Trip Health Ltd. (TSX:FTRP) (NASDAQ:FTRP) reported its third fiscal quarter 2022 results for the three months ended December 31, 2021 and provided a business update.

7 months ago - Benzinga